Jefferies Financial Group Reaffirms “Buy” Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating restated by Jefferies Financial Group in a note issued to investors on Thursday, Digital Look reports. They presently have a GBX 2,025 price objective on the stock. Jefferies Financial Group‘s price objective suggests a potential upside of 22.73% from the stock’s current price.

A number of other research firms also recently issued reports on HIK. Citigroup raised their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Berenberg Bank increased their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating. According to MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of GBX 1,998.75.

Hikma Pharmaceuticals Stock Down 2.8%

Shares of Hikma Pharmaceuticals stock opened at GBX 1,650 on Thursday. The stock has a market capitalization of £3.41 billion, a PE ratio of 9.38, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The company has a 50-day simple moving average of GBX 1,627.89 and a two-hundred day simple moving average of GBX 1,508.93. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 1,762.

Insider Activity

In other news, insider Tobias Hestler purchased 7,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. Company insiders own 22.26% of the company’s stock.

Trending Headlines about Hikma Pharmaceuticals

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Hikma raised its growth outlook for branded medicines, a positive offset to weakness elsewhere in the business. Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance
• Neutral Sentiment: The company maintained its 2026 revenue guidance and narrowed its operating profit forecast to $740–$760 million. The tighter range gives investors more clarity, but the outlook remains a key focus. Hikma Pharmaceuticals Maintains 2026 Revenue Guidance and Narrows Operating Profit Forecast
• Neutral Sentiment: Jefferies reaffirmed its Buy rating with a GBX 2,025 target, while Deutsche Bank cut its target from GBX 2,050 to GBX 2,000 but retained a Buy rating. Deutsche Bank rating information
• Negative Sentiment: Hikma lowered its outlook for Injectables. That business outlook revision is the clearest near-term headwind and likely weighs on sentiment despite the brighter branded-medicines forecast. Hikma Pharmaceuticals shares down as cuts Injectables outlook

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.